Abstract
The COVID-19 pandemic caused by SARS-CoV-2 is a global health emergency warranting the development of targeted treatment. The main protease M pro is considered as a key drug target in coronavirus infections because of its vital role in the proteolytic processing of two essential polyproteins required for the replication and transcription of viral RNA. Targeting and inhibiting the M pro activity represents a valid approach to prevent the SARS-CoV-2 replication and spread. Based on the structure-assisted drug designing, here we report a circadian clock-modulating small molecule “SRT2183” as a potent inhibitor of M pro to block the replication of SARS-CoV-2. The findings are expected to pave the way for the development of therapeutics for COVID-19.
Keywords: COVID-19; Circadian clock-modulating molecules; SARS-CoV-2 Mpro; SRT2183; inhibitors; main protease; pandemic; targeted therapy.
【저자키워드】 COVID-19, pandemic, main protease, inhibitors, SARS-CoV-2 Mpro, targeted therapy, Circadian clock-modulating molecules, SRT2183, 【초록키워드】 Treatment, SARS-CoV-2, Coronavirus infection, Therapeutics, COVID-19 pandemic, Transcription, protease, inhibitors, Replication, MPro, SARS-CoV-2 Mpro, Spread, Coronavirus infections, drug target, small molecule, Viral RNA, targeted therapy, inhibitor, SARS-CoV-2 replication, SRT2183, health emergency, M pro, targeting, polyprotein, circadian clock, Proteolytic processing, replication of SARS-CoV-2, approach, Prevent, caused, required, expected, inhibiting, the SARS-CoV-2, 【제목키워드】 inhibitors of SARS-CoV-2, M pro, modulating, pharmacological intervention,